Kartzinel R, Shoulson I, Calne D B
Neurology. 1976 Jun;26(6 PT 1):511-3. doi: 10.1212/wnl.26.6.511.
A double-blind crossover study was performed in 12 patients with idiopathic parkinsonism to compare their response to bromocriptine with their response to previous optimal drug treatment, including levodopa. There was a 26 percent overall improvement with bromocriptine; rigidity, tremor, and facial expression showed the greatest response. Seven of eight patients who were taking levodopa at the beginning of the study was taken off the drug completely. Adverse reactions were transient and dose-dependent. Bromocriptine promises to be an effective new therapeutic agent in the treatment of idiopathic parkinsonism.
对12例特发性帕金森病患者进行了一项双盲交叉研究,以比较他们对溴隐亭的反应与对包括左旋多巴在内的先前最佳药物治疗的反应。溴隐亭治疗后总体改善率为26%;僵硬、震颤和面部表情的改善最为显著。研究开始时正在服用左旋多巴的8例患者中有7例完全停用了该药。不良反应是短暂的且与剂量相关。溴隐亭有望成为治疗特发性帕金森病的一种有效的新型治疗药物。